Research programme: dengue fever virus vaccine - GenVec/Naval Medical Research Center

Drug Profile

Research programme: dengue fever virus vaccine - GenVec/Naval Medical Research Center

Alternative Names: Dengue fever vaccine - GenVec

Latest Information Update: 09 Jul 2014

Price : $50

At a glance

  • Originator GenVec; Naval Medical Research Center
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dengue

Most Recent Events

  • 28 Mar 2014 Discontinued for Dengue in USA (Parenteral) before 28 March 2014
  • 25 Jan 2011 Early research in Dengue in USA (Parenteral)
  • 25 Jan 2011 GenVec establishes CRADA with US Naval Medical Research Center for the development of Dengue fever virus vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top